We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · June 17, 2021

Efficacy and Safety of Baricitinib in the Treatment of Adults With Alopecia Areata

Journal of the American Academy of Dermatology

 

Additional Info

Journal of the American Academy of Dermatology
Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults With Alopecia Areata: Phase 2 Results From a Randomized Controlled Study
J Am Acad Dermatol 2021 Jun 03;[EPub Ahead of Print], B King, J Ko, S Forman, M Ohyama, N Mesinkovska, G Yu, J McCollam, M Gamalo, J Janes, E Edson-Heredia, K Holzwarth, Y Dutronc

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading